November 4, 2015
Crinetics Pharmaceuticals, an innovative therapeutics company focused on specialty endocrine disorders, has announced the completion of a $40 million Series A financing led by 5AM Ventures, Versant Ventures, and Vivo Capital. The company plans to use the proceeds to advance development of its small molecule somatostatin agonist program to clinical proof-of-concept for the treatment of acromegaly, as well as to move additional programs into development. Latham & Watkins LLP represented Crinetics Pharmaceuticals in the completion of its Series A financing with a corporate team led from the firm’s San Diego office by partner Cheston Larson, with associates Christopher Geissinger and Alaina Ellis. Advice has also been provided on benefits and compensations matters by counsel Holly Bauer in San Diego.